DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in TPOXX is tecovirimat. One supplier is listed for this compound. Additional details are available on the tecovirimat profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 208627
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Approval Date:||Jul 13, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jul 13, 2025|
|Regulatory Exclusivity Use:||INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG|
|Regulatory Exclusivity Expiration:||Jul 13, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||⤷ Try it Free||Patent Expiration:||May 3, 2027||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG|
Complete Access Available with Subscription